This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated September 2026 quarter revenue up 2.2%, profit after tax down 57.3% year on year
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts less than Nifty Midcap 150 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated quarter ended September 30, 2026, revenue from operations was Rs 43,889 million versus Rs 42,955 million a year earlier, up 2.2%; profit after tax was Rs 567 million versus Rs 1,328 million. A Rs 67 million exceptional charge was booked, with segment comparatives restated. Consolidated half-year: revenue Rs 87,249 million versus Rs 82,374 million; profit after tax Rs 1,935 million versus Rs 2,220 million.
Revenue grew only 2.2% while profit after tax fell 57.3%; weaker earnings could weigh on shareholder sentiment.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹4,389 Cr | ₹4,296 Cr | +2.2% |
| Operating profit | ₹27.00 Cr | ₹90.20 Cr | −70.1% |
| Profit after tax | ₹56.70 Cr | ₹132.8 Cr | −57.3% |
| EBITDA margin | 18.8% | 19.2% | −0.4 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.